← Back to all trials
Completed
NCT05724979
Outcome of Using Sperm Bound to the Zona Pellucida of Immature Oocytes for Intracytoplasmic Sperm Injection (ICSI)
Conditions: Intracytoplasmic Sperm Injection, Infertility, Male
Sex: All
Ages: 18 Years – 38 Years
Healthy volunteers: 1
Phase: NA
Enrollment: 24
Sponsor: Al-Azhar University
Location: Egypt
Summary
In vivo, the zona pellucida (ZP) of the oocyte can bind to normally functional sperm.
The ZP-sperm interaction is one of the final steps of natural selection during their journey in the female reproductive tract.
In the current study, we evaluated the ability of the ZP of immature oocytes to harvest the fittest sperm.
We compared the embryological outcomes of intracytoplasmic sperm injection (ICSI) using conventionally selected sperm (control group) and ZP-bound sperm (intervention group).
Our results showed no statistically significant superiority for the ZP binding technique over the conventional sperm selection with respect to the rates of fertilization and cleavage.
However; the rates of blastocyst formation and high-quality blastocysts were significantly improved in the intervention group compare to the control group.
These findings imply that the proposed technique can serve as a cost-effective and natural sperm selection method that has the potential to enhance the embryological and clinical outcomes of intracytoplasmic sperm injection (ICSI).
Eligibility Criteria
Inclusion Criteria:Couples must be diagnosed with infertility and undergoing ICSI cycle.The age range for all female subjects must be between 21 and 38 years old, and their male partners must be older than 24 years old and above 50 years old.Patients must produce at least two mature oocytes (one to be used for control and one for treatment) and one immature oocyte (to be used for selecting sperm).Males must show at least 10% total sperm motilityExclusion Criteria:Cases where the female was younger than 21 years or older than 38 years old.Patients that had less than two mature oocytesPatients with no immature oocytesPatients with low oocyte quality.Cases with less than 10% motility or those with no motility such as PESA, TESA, and TESE cases.
Source: ClinicalTrials.gov (NCT05724979). StuddyBuddy aggregates publicly available trial information.
